Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders Trial
Recruiting · NCT06488105 · Interventional (participants receive a specific treatment) · Lead sponsor: Wake Forest University Health Sciences
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders (EMERALD) is a protocolized intervention based on American College of Cardiology/American Heart Association and US Preventive Services Task Force guidelines designed to initiate preventive cardiovascular care for emergency department patients being evaluated for acute coronary syndrome. The overarching goals of this proposal are to (1) determine the efficacy of EMERALD at lowering low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein cholesterol (non-HDL-C) among at-risk Emergency Department (ED) patients who are not already receiving guideline-directed outpatient preventive care and (2) inform our understanding of patient adherence and determinants of implementation for ED-based cardiovascular disease prevention strategies.
Who can take part
Inclusion criteria
- Evaluation for Acute Coronary Syndrome
- Age 40-75 Years
- 10-year Atherosclerotic Cardiovascular Disease (ASCVD) Risk ≥7.5% or Known Diabetes or
- Known ASCVD:
- Myocardial Infarction
- Unstable Angina
- Percutaneous Coronary Intervention
- Coronary Artery Bypass Graft
- Stroke
- Transient Ischemic Attack
- Peripheral Artery Disease
Exclusion criteria
- ST-Segment Elevation Myocardial Infarction (STEMI) Activation
- ST Depression \>1 mm in Contiguous Leads
- On a Lipid Lowering Agent (Statin, PCSK9 Inhibitor, Bempedoic Acid, Ezetimibe, Inclisiran, etc.)
- Inability to Return for 30-day Follow-up
- Unstable Vitals (Systolic blood pressure \<90, HR \>120 or \<50, oxygen saturation \<90%)
- Statin Intolerance
- Any Resulted High-Sensitivity Troponin I ≥100 ng/L
- End-stage renal disease (ESRD) and/or glomerular filtration rate (GFR) \<30 mL/min/1.73 m2
- Liver Cirrhosis
- Pregnancy
- Anticipated Hospitalization
- Life Expectancy \<1 Year
- Transfer from Another Hospital
- Prisoner
- Non-English Speaking
Where it is running
1 location listed across 1 US state.
- Wake Forest University Health Sciences - Winston-Salem, North Carolina, United States